<DOC>
	<DOCNO>NCT02058719</DOCNO>
	<brief_summary>This study plan learn pulmonary complication human immunodeficiency virus/acquired immunodeficiency syndrome ( HIV/AIDS ) . Even though antiretroviral therapy ( ART ) dramatically decrease number opportunistic infection death HIV infect patient , pulmonary complication ( include chronic obstructive pulmonary disease ( COPD ) development pneumonia result decrease lung function ) HIV/AIDS continue major cause morbidity mortality population . The mechanisms underlying increase risk COPD decrease lung function HIV infect individual well understand need study . The investigator hypothesize immunoregulatory consequence immunosuppressive lung milieu secondary HIV cigarette smoke combine increase risk lung infection injury HIV infect smoker , hasten development COPD . The mechanism directly test use blood bronchial alveolar lavage ( BAL ) cell smokers nonsmoker without HIV infection .</brief_summary>
	<brief_title>Immunosuppressive Effects Smoking HIV-1 Development Lung Disease</brief_title>
	<detailed_description>The first component study longitudinal , prospective , 24 week study effect HIV-1 infection innate acquire immunity lung ( Cohort A ) . The second component study cross-sectional , case-control study lung function immune dysregulation HIV-1 infected person long-term ART ( Cohort B ) . Cohort A consist 120 subject , stratify HIV-1 smoking status Cohort B consist 90 subject stratify chronic obstructive pulmonary disease ( COPD ) HIV-1 infection .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Inclusion Criteria ( Cohort A ) : Subjects chronic HIV1 infection ( Cohorts A1 A2 ) ART na√Øve ART &gt; 6 month ( Cohorts A1 A2 ) HIV1 RNA level &gt; 1,000 copies/ml ( Cohorts A1 A2 ) HIV1 seronegative highrisk exposure past 30 day ( Cohorts A3 A4 ) 18 year old ( All Cohort A ) Active cigarette smoker ( Cohorts A1 A3 ) Inclusion Criteria ( Cohort B ) : Age 30 70 year Subjects chronic HIV1 infection ( Cohorts B1 B2 ) Subjects stable 3drug ART regimen plasma HIV1 RNA &lt; 50 copies/mL past 6 month ( Cohorts B1 B2 ) HIV1 seronegative highrisk exposure past 30 day ( Cohort B3 ) COPD : forced expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) &lt; 70 % forced expiratory volume ( FEV ) , 45100 % predict ( Cohort B1 B3 ) NonCOPD : FEV/FVC &gt; 70 % FEV , &gt; 80 % predict ( Cohort B2 ) Exclusion Criteria ( Cohort A B ) : Pregnancy Weight le 110 pound ( venipuncture ) Patient inability participate study undergo venipuncture bronchoscopy procedure Use systemic inhaled corticosteroid past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>